Prometrium Adolescent (12, 17) Dosing

Why Prometrium Is Used Off-Label in Adolescents

Prometrium carries an FDA-approved indication only for secondary amenorrhea and endometrial protection in postmenopausal women on estrogen therapy 1. No randomized controlled trial has enrolled participants younger than 18 for this specific formulation. Pediatric endocrinologists and adolescent gynecologists still reach for micronized progesterone when a teenager needs progestational support because the safety profile compares favorably to synthetic progestins like medroxyprogesterone acetate (MPA).

The PEPI trial (N=875) established that micronized progesterone provided effective endometrial protection while preserving HDL cholesterol levels better than MPA 2. Although PEPI enrolled postmenopausal women aged 45, 64, its pharmacologic findings on endometrial safety and lipid neutrality inform the rationale for choosing micronized progesterone over MPA in younger patients who may be on therapy for years. The American College of Obstetricians and Gynecologists (ACOG) recognizes micronized progesterone as an option for managing abnormal uterine bleeding across reproductive age groups 3.

Adolescent indications that prompt off-label prescribing include hypothalamic amenorrhea from low energy availability (common in athletes and patients with eating disorders), polycystic ovary syndrome (PCOS) requiring cyclic endometrial shedding, and gender-affirming hormone therapy. Each scenario demands different dosing logic, and body weight matters more in a 13-year-old than in an adult.

Dosing Protocols by Indication

The correct dose depends on why the adolescent needs progesterone. There is no single universal protocol. Clinicians typically extrapolate from adult data and adjust based on the patient's weight, Tanner stage, and treatment goals.

Secondary amenorrhea. For inducing a withdrawal bleed, the standard approach mirrors the adult regimen: 200 mg orally at bedtime for 10 days 1. Some pediatric endocrinologists start at 100 mg for smaller adolescents (body weight below 45 kg) and titrate upward if no withdrawal bleed occurs within 7 days of completing the course. A 2019 review in the Journal of Pediatric and Adolescent Gynecology confirmed that cyclic oral progesterone remains first-line for non-structural causes of secondary amenorrhea in teens 4.

Dysfunctional uterine bleeding. ACOG Committee Opinion No. 651 addresses heavy menstrual bleeding in adolescents, recommending progestin-based therapy when medical management is appropriate 5. Micronized progesterone at 200 mg nightly for 12 days during the luteal phase is one approach; an alternative is continuous daily dosing at 100 mg for adolescents who need ongoing cycle regulation without estrogen exposure.

Endometrial protection with estrogen therapy. Teens receiving estrogen for primary ovarian insufficiency, Turner syndrome, or hypothalamic amenorrhea need progestational opposition to prevent endometrial hyperplasia. The Endocrine Society recommends cyclic progesterone for 10 to 14 days per month in these cases 6. Doses of 200 mg at bedtime for 12 days are standard. The PEPI data support this duration as sufficient for complete secretory transformation of the endometrium 2.

Gender-affirming care. Progesterone is sometimes added to feminizing hormone regimens for transgender adolescents, though the Endocrine Society's 2017 guidelines do not specifically recommend it as part of standard feminizing therapy 6. When prescribed, doses of 100 to 200 mg at bedtime are typical. Evidence remains limited, and prescribing decisions rely heavily on clinical judgment and shared decision-making with the patient and family.

Pharmacokinetics in Younger Patients

Micronized progesterone reaches peak serum concentration approximately 3 hours after oral ingestion when taken with food 1. Taking it at bedtime has a practical benefit: the sedative effects of allopregnanolone, a neuroactive metabolite, coincide with sleep rather than school hours. This is not trivial. Adolescents report higher rates of next-day drowsiness than adults, likely because hepatic first-pass metabolism generates proportionally more allopregnanolone in smaller patients with lower body mass 7.

Food increases bioavailability by 25 to 50%, per the Prometrium prescribing information 1. This creates a dosing nuance: a teenager who takes the capsule with a late snack will absorb more drug than one who takes it on an empty stomach. Clinicians should counsel families about consistent timing relative to meals. A small crossover pharmacokinetic study (N=12 healthy premenopausal women) showed that the AUC of oral micronized progesterone varied by nearly 2-fold depending on fed versus fasted state 8.

Hepatic metabolism via CYP3A4 and CYP2C19 is the primary elimination pathway. Adolescents on medications that induce CYP3A4 (certain anti-epileptic drugs like carbamazepine) may require higher progesterone doses to achieve therapeutic levels 9. Conversely, CYP3A4 inhibitors such as ketoconazole can raise progesterone exposure.

Safety and Side-Effect Profile in Teens

The most common side effects in adults, per the FDA label, include dizziness (reported in 24% of the 200 mg group versus 4% on placebo in the secondary amenorrhea trial), headache, and abdominal pain 1. Adolescent-specific safety data from controlled trials do not exist, so clinicians rely on post-marketing surveillance and case series.

Sedation and school performance. Drowsiness is dose-dependent. A 2003 study by de Lignieres demonstrated that oral micronized progesterone produces significantly more somnolence than vaginal progesterone because of higher allopregnanolone production from hepatic first-pass metabolism 10. For adolescents, this means bedtime-only dosing is not just a recommendation. It is a requirement for functional school attendance.

Mood effects. Progesterone's neuroactive metabolites act on GABA-A receptors, which can produce anxiolytic effects in some patients and dysphoria in others 11. Adolescents with a history of depression or anxiety need mood monitoring during therapy. The AAP and AACAP recommend screening with validated tools such as the PHQ-A at baseline and at 4 to 8 week intervals when initiating hormonal therapies in teens 12.

Peanut oil allergy. Prometrium capsules are formulated with peanut oil. The FDA label carries a specific contraindication for patients with known peanut allergy 1. For peanut-allergic adolescents, compounded micronized progesterone in a non-peanut oil base or vaginal progesterone suppositories are alternatives. The prevalence of peanut allergy in U.S. children and adolescents is approximately 2.5% according to NIAID data 13, so this is not a rare concern.

Thrombotic risk. Oral micronized progesterone appears to carry a lower venous thromboembolism (VTE) risk than synthetic progestins. The ESTHER study found no significant increase in VTE risk with micronized progesterone (OR 0.7 to 95% CI 0.3, 1.9), compared with a 3.9-fold risk increase with norpregnane derivatives 14. This is relevant for adolescent patients because hormonal contraceptive counseling already requires VTE risk discussion, and selecting a progestin with a favorable thrombotic profile matters for long-term safety.

Monitoring During Adolescent Therapy

Prescribing progesterone to a growing patient requires a monitoring framework that adult protocols do not address. Five domains need tracking.

Growth velocity. Progesterone can accelerate epiphyseal closure when combined with estrogen. Serial height measurements every 3 to 6 months are standard. If an adolescent is still in active linear growth (Tanner stages II, IV), bone age radiographs every 12 months help assess whether therapy is advancing skeletal maturation beyond chronologic age 15.

Bone mineral density. Adolescence is the critical window for peak bone mass accrual. The International Society for Clinical Densitometry recommends DXA monitoring for adolescents on hormone therapy if treatment duration exceeds 12 months, using Z-scores rather than T-scores 16. Progesterone alone has not been shown to impair bone accrual, but the underlying condition (e.g., hypothalamic amenorrhea with low estrogen) may do so.

Menstrual pattern documentation. Tracking cycle length, flow volume, and timing of withdrawal bleeds helps assess therapeutic response. Digital menstrual tracking apps provide better data than recall alone. The absence of a withdrawal bleed after completing a progesterone course should prompt re-evaluation for pregnancy, anatomic abnormality, or inadequate estrogen priming 3.

Hepatic function. The FDA label recommends discontinuation if cholestatic jaundice or hepatic dysfunction develops 1. Baseline liver function tests (ALT, AST, bilirubin) before starting therapy and repeat testing at 3 months is a reasonable approach, though no formal pediatric guideline mandates a specific interval.

Mental health screening. As noted above, mood assessment at baseline and every 4 to 8 weeks during the first 3 months of therapy is prudent. The PHQ-A takes under 5 minutes and can be completed in a waiting room 12.

When to Choose Vaginal Over Oral Progesterone

Vaginal micronized progesterone bypasses hepatic first-pass metabolism, producing lower serum progesterone levels but higher uterine tissue concentrations. This "uterine first-pass effect" was described by de Ziegler et al. and has been confirmed in multiple pharmacokinetic studies 17. For adolescents, vaginal administration may be appropriate in two scenarios.

First, when sedation from oral dosing interferes with daily function despite bedtime administration. Some teens report next-morning grogginess severe enough to affect academic performance. Vaginal progesterone produces far less allopregnanolone and avoids this problem 10.

Second, when peanut allergy precludes use of Prometrium capsules. Vaginal progesterone products such as Endometrin (progesterone insert, 100 mg) and Crinone (progesterone gel, 8%) do not contain peanut oil 18. Neither is FDA-approved for adolescent use, but both are prescribed off-label.

Patient preference and comfort matter. Many adolescents find vaginal administration unacceptable. Shared decision-making should include a frank discussion about route of administration, and clinicians should not assume acceptance. If the oral route is chosen and sedation is manageable, it remains the simplest option.

Drug Interactions Relevant to Adolescents

Teenagers take medications that adults typically do not, and some interact with progesterone metabolism.

Anti-epileptic drugs. Carbamazepine, phenytoin, and phenobarbital are potent CYP3A4 inducers that reduce progesterone exposure. Adolescents on these medications may need progesterone dose increases of 50 to 100% or serum level monitoring to confirm adequate exposure 9.

SSRIs. Fluoxetine and fluvoxamine inhibit CYP2C19, which may modestly increase progesterone levels. This interaction is rarely clinically significant but warrants awareness given the frequency of SSRI use in adolescents. A 2018 pharmacovigilance review found no serious adverse events attributable to SSRI-progesterone co-administration 19.

Isotretinoin (Accutane). Commonly prescribed for severe adolescent acne, isotretinoin has no known pharmacokinetic interaction with progesterone. Both drugs are teratogenic. Adolescents on both medications require two forms of contraception per iPLEDGE requirements, and the addition of progesterone does not fulfill that contraceptive mandate because cyclic micronized progesterone at 200 mg for 10 to 14 days does not reliably suppress ovulation 20.

Special Populations Within Adolescence

Turner syndrome. Girls with 45,X karyotype require estrogen replacement starting at age 11, 12 and progesterone addition after 2 years of estrogen or at the onset of breakthrough bleeding. The Turner Syndrome Society guidelines recommend cyclic micronized progesterone 200 mg for 10 days monthly once estrogen dose reaches adult levels 21.

Athletes with relative energy deficiency (RED-S). The IOC 2023 consensus statement on RED-S identifies menstrual dysfunction as a clinical marker of low energy availability 22. Progesterone-induced withdrawal bleeding can mask ongoing energy deficiency by creating the appearance of normal cycles. The primary treatment is nutritional rehabilitation, not hormone replacement. Progesterone should only be added for endometrial protection if estrogen is prescribed and energy availability remains insufficient despite intervention.

PCOS in adolescents. The 2023 International Evidence-Based Guidelines for PCOS recommend cyclic progestin therapy for endometrial protection in adolescents who are not candidates for combined hormonal contraceptives 23. Micronized progesterone 200 mg for 12 to 14 days every 1 to 3 months is the recommended regimen when the goal is withdrawal bleeding without ovulation suppression.

Practical Prescribing Checklist

Before writing a Prometrium prescription for a patient aged 12, 17, confirm these seven items: (1) the indication is clearly documented, (2) peanut allergy has been ruled out, (3) pregnancy test is negative, (4) baseline liver function tests are within normal limits, (5) a mood screening tool has been administered, (6) growth velocity and Tanner stage are recorded, and (7) the family understands this is an off-label use. The dose for most adolescent indications is 200 mg orally at bedtime for 10 to 14 days per cycle, reduced to 100 mg for patients weighing under 45 kg or experiencing significant sedation.